Desmoid Tumors Drug Pipeline Analysis Report 2025

Desmoid tumors (DT) are rare, non-metastatic soft tissue tumors that arise from fibroblasts and can be locally aggressive. They account for approximately 3-5 cases per million people annually. With the increasing focus on developing better therapies, the desmoid tumor drug pipeline is expanding, offering promising treatment options. The growing emphasis on personalized medicine and improved therapeutic products is expected to enhance patient outcomes and fuel market growth, addressing the unmet medical needs in desmoid tumor management.

Report Coverage

The Desmoid Tumors Drug Pipeline Insight Report by the publisher gives comprehensive insights into desmoid tumors therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for desmoid tumors. The desmoid tumors report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The desmoid tumors pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with desmoid tumors treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to desmoid tumors.

Desmoid Tumors Drug Pipeline Outlook

Desmoid tumors are rare, non-cancerous growths that develop in connective tissues, often in the abdomen, arms, legs, or chest. They arise due to mutations in the CTNNB1 gene or from conditions like familial adenomatous polyposis (FAP). Although benign, they can infiltrate surrounding tissues, causing pain and functional impairment. Trauma, surgery, or hormonal factors may trigger their growth.

Desmoid tumors are treated through a multidisciplinary approach. Treatment options include active surveillance for slow-growing tumors, surgery for resectable cases, and radiation therapy for inoperable tumors. Systemic therapies, such as anti-hormonal drugs, nonsteroidal anti-inflammatory drugs (NSAIDs), or targeted therapies like tyrosine kinase inhibitors, are used for aggressive or recurrent tumors. Treatment choice depends on tumor size, location, and progression.

Desmoid Tumors Epidemiology

The global incidence of desmoid tumors (DT) is approximately 3-5 cases per million person-years, with the highest frequency in adults aged 20-44 years, particularly women. In the United States, around 1,000 new cases are diagnosed annually, with 90% linked to mutations in the ß-catenin gene (CTNNB1). In Europe, the incidence is 3 cases per million person-years, with women affected 2.2-3.9 times more than men.

Desmoid Tumors - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of desmoid tumors drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Monoclonal Antibodies
• Gene Therapies
• Peptides
• Biologics

By Route of Administration

• Oral
• Parenteral
• Others

Desmoid Tumors - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total desmoid tumors clinical trials.

Desmoid Tumors - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the desmoid tumors pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and biologics. The desmoid tumors report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for desmoid tumors.

Desmoid Tumors Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the desmoid tumors drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed desmoid tumors therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in desmoid tumors clinical trials:

• Immunome, Inc.
• SpringWorks Therapeutics, Inc.
• Parabilis Medicines, Inc.
• Pfizer
• Novartis
• INSYS Therapeutics Inc.
• Recursion Pharmaceuticals Inc.

Desmoid Tumors Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for Desmoid Tumors. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of desmoid tumors drug candidates.

Drug: AL102

AL102, sponsored by Immunome, Inc., is an investigational small molecule gamma secretase inhibitor being evaluated in the Phase II/III RINGSIDE trial for progressive desmoid tumors. The study aims to assess the efficacy and safety of AL102. This potential once-daily oral treatment shows promise in being more effective than OGSIVEO™ (nirogacestat), the first FDA-approved therapy for desmoid tumors.

Drug: Nirogacestat

Nirogacestat, sponsored by Stanford University, is currently being studied in a Phase II trial for desmoid tumors. The objective is to evaluate the efficacy of systemic oral Nirogacestat combined with Cryoablation. Patients receive Nirogacestat for three cycles (28 days each), followed by cryoablation, and continue treatment through 26 cycles over 24 months, assessing disease progression, pain relief, and quality of life.

Reasons To Buy This Report

The Desmoid Tumors Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for desmoid tumors. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into desmoid tumors collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Desmoid Tumors - Pipeline Insight Report

• Which companies/institutions are leading the desmoid tumors drug development?
• What is the efficacy and safety profile of desmoid tumors pipeline drugs?
• Which company is leading the desmoid tumors pipeline development activities?
• What is the current desmoid tumors commercial assessment?
• What are the opportunities and challenges present in the desmoid tumors drug pipeline landscape?
• What is the efficacy and safety profile of desmoid tumors pipeline drugs?
• Which company is conducting major trials for desmoid tumors drugs?
• Which companies/institutions are involved in desmoid tumors collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in desmoid tumors?

This product will be delivered within 3-5 business days.